

**AED U.S. Sales Dollars Associated with Epilepsy Indications per Prescription  
2009 – February 2015**

	2009	2010	2011	2012	2013	2014	Jan–Feb 2015	Total
<b>Sales Dollars (\$MM)</b>								
VIMPAT®	\$35.5	\$135.8	\$227.5	\$338.6	\$475.2	\$629.0	\$114.9	\$1,956.5
Total Branded	\$1,766.9	\$1,462.4	\$1,514.4	\$1,592.9	\$1,732.2	\$2,025.7	\$360.8	\$10,455.1
Total Generic	\$587.4	\$529.1	\$529.5	\$481.7	\$664.0	\$744.0	\$121.6	\$3,657.3
<b>Prescriptions (000's)</b>								
VIMPAT®	83.6	312.0	502.3	659.6	819.7	972.6	171.8	3,521.6
Total Branded	7,411.8	5,033.3	4,631.9	4,115.4	3,648.2	3,585.3	574.5	29,000.5
Total Generic	16,733.8	19,128.3	20,133.0	21,386.0	23,148.7	24,560.6	4,023.0	129,113.4
<b>Sales per Prescription</b>								
VIMPAT®	\$424.63	\$435.32	\$452.92	\$513.33	\$579.70	\$646.74	\$668.86	\$555.58
Total Branded	\$238.39	\$290.54	\$326.95	\$387.06	\$474.79	\$564.98	\$627.91	\$360.52
Total Generic	\$35.10	\$27.66	\$26.30	\$22.52	\$28.69	\$30.29	\$30.24	\$28.33

**Notes:**

I understand from counsel that UCB's standard business practice for evaluating the performance of VIMPAT® in the AED marketplace is to "factor" sales information related to certain AEDs to determine dollar sales that are associated with epilepsy.

VIMPAT® launched May 2009.

**Sources:**

Sales Dollars (\$MM): Ex. 2176, p. 4 (IMS)

Prescriptions (000s): Ex. 2171, p. 4 (IMS)